These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22338018)

  • 1. New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
    Dong M; Phan AT; Yao JC
    Clin Cancer Res; 2012 Apr; 18(7):1830-6. PubMed ID: 22338018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
    Papaxoinis G; Syrigos K; Saif MW
    Discov Med; 2016 May; 21(117):391-402. PubMed ID: 27355335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
    Eriksson B
    Curr Opin Oncol; 2010 Jul; 22(4):381-6. PubMed ID: 20473165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent studies show promise for treating rare pancreatic tumors.
    Peres J
    J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
    [No Abstract]   [Full Text] [Related]  

  • 7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the mTOR signaling pathway in neuroendocrine tumors.
    Chan J; Kulke M
    Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG; Strosberg JR; Halfdanarson TR
    Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
    Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.